< Back to previous page
Project
Optimising CD70-specific T cell therapy for solitary and haematological malignancies
The strong efficacy of CD19-targeted CAR-T cell therapy in various hematologic malignancies is evident. This project initially focuses on the efficacy of an in-house developed, nanobody-based CAR-T cell therapy targeting CD70. Subsequently, the efficacy will be optimized via biparatopic CAR-T cell receptors as well as via HLA independent T-cell receptors to finally test this in PDX models.
Date:1 Nov 2022 → 31 Oct 2023
Keywords:target, CAR-T cell therapy, optimisation, malignancy
Disciplines:Applied immunology